E. E. Mulkearns-Hubert

This study shows that HFE promotes glioblastoma growth by regulating iron homeostasis and oxidative stress, with HFE loss inducing apoptosis and extending survival.

This study identifies VRK1 as a synthetic lethal target in VRK2-methylated glioblastoma by showing that VRK1 inhibition leads to tumor growth inhibition in xenograft models.

This study identifies WDR5 as an essential epigenetic regulator in therapy-resistant glioblastoma cancer stem cells and shows that WDR5 inhibitors disrupt CSC maintenance and tumor growth.

This study demonstrates that a cell-penetrating peptide targeting the Cx26/NANOG/FAK complex inhibits tumor growth and alters NANOG activity in triple-negative breast cancer.

The paper develops a mouse model to study how surgery and steroids affect immune responses in glioblastoma, finding systemic lymphocyte reduction and correlations with tumor growth and patient outcomes.

This study identifies clofazimine as a Cx46 inhibitor that targets glioblastoma cancer stem cells by disrupting gap junction communication, enhancing the efficacy of temozolomide.